Background-Cardiac resynchronization therapy (CRT) is an effective therapy for patients with moderate to severe heart failure and prolonged QRS duration. 
tural and functional improvements with continuous CRT will be sustained. The aim of the present study was 3-fold: To determine, via quantitative echocardiography in a large patient cohort, whether reverse LV remodeling persisted after 1 year of continuous CRT; to assess the proportion of patients in whom reverse remodeling was sustained; and to ascertain whether differences existed between ischemic and nonischemic patients after 12 months.
Methods
The Multicenter InSync Randomized Clinical Evaluation (MIRACLE) study was a prospective, double-blind, controlled evaluation of patients receiving optimal medical heart failure therapy who were randomized to CRT ON or CRT OFF and followed up for a minimum of 6 months. 1 The primary end points were improvement in NYHA symptom class, 6-minute hall walk distance, and qualityof-life (QoL) score with the Minnesota Living with Heart Failure (MLWHF) Questionnaire. Patients in the MIRACLE study who were initially randomized to CRT ON were followed up for up to 12 months, at which time they underwent clinical assessment and a repeat quantitative Doppler echocardiogram to determine whether the reverse remodeling reported at 6 months 8 was sustained at 12 months.
The study population consisted of 228 patients with QRS duration Ն130 ms, LV end-diastolic diameter (EDD) Ն55 mm, and an LV ejection fraction (LVEF) Յ35%. All patients were in NYHA symptom class III/IV and on an optimal heart failure medical regimen that was unchanged for a minimum of 1 month for diuretics, ACE inhibitors/ARBs, and digitalis and a minimum of 3 months for ␤-blockers before randomization. The dose of ␤-blockers and ACE inhibitors during the first 6 months of the study (during the double-blind period) was kept constant, but from 6 to 12 months, the study was open-label, during which changes in pharmacological therapy were at the discretion of the treating physician. Patients were subsequently divided by origin of heart failure into 2 groups, ischemic and nonischemic, to assess differences in LV reverse remodeling between 6 and 12 months. The treating physician determined assignment to ischemic etiology on the basis of clinical history of prior myocardial infarction with ECG evidence of infarct location, prior percutaneous coronary intervention, or prior coronary bypass surgery, similar to the assignment used in other CRT trials 2,4,9,10 (MIRACLE ICD, MUSTIC, COMPANION [Comparison of Medical Therapy, Pacing, and Defibrillation on Heart Failure], and CARE-HF [Cardiac Resynchronization-Heart Failure]). Coronary angiography was not a prerequisite for the assignment of an ischemic cause of heart failure in the MIRACLE trial or the trials described above and may have led to misclassification of patients, and as such, this is a potential limitation of the present study.
The timing of the delay between atrial sensed activity and delivery of simultaneous biventricular pacing was individually adjusted in all patients to maximize LV filling without truncation of left atrial contraction, using a Doppler echocardiographic method previously described. 11 Doppler echocardiograms at baseline before device implantation and at 6 and 12 months after initiation of CRT were analyzed in a core laboratory by a single sonographer blinded to treatment group and study sequence. Although ventricular pacing pulses were visible on the simultaneously recorded ECG, each echocardiogram was analyzed without reference to previous echocardiographic studies. Videotaped echocardiograms were analyzed on a TomTec computer workstation to obtain LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) by the method of discs. 12 LVEF was calculated as: (EDVϪESV)/EDVϫ100%). LV mass was calculated at end diastole as 5/6ϫLV short-axis myocardial areaϫLV cavity lengthϫdensity of muscle (1.055). LV shape was assessed as the ratio of short-axis cavity area to the apical 4-chamber cavity area at end diastole and end systole. In an effort to determine the proportion of patients who respond to therapy when using LV cavity volumes as the determinant of response, the percentage of patients with improved LVEDV and LVESV from their baseline values were calculated with their respective 95% confidence intervals (CIs).
The severity of mitral regurgitation (MR) was assessed from orthogonal apical echocardiographic images as the average of the planimetered areas of the Doppler color flow regurgitant jet within the left atrium and as the ratio of regurgitant jet area to left atrial area. Pulsed-wave Doppler velocity signals of transmitral flow were recorded with the sample volume at the tips of the mitral valve leaflets at a sweep speed of 100 mm/s. Peak velocities were measured during passive diastolic filling (E wave) and left atrial systolic contraction (A wave), and the velocity ratio (E/A) was calculated. The deceleration time (DT) of the E wave, LV filling time, and the isovolumic relaxation time (IVRT) were also measured. The myocardial performance index (MPI) was calculated as the sum of the isovolumic contraction time (ICT) and IVRT divided by the ejection time (ET): MPIϭ(ICTϩIVRT)/ET. 13 The interventricular mechanical delay, which was used as an indicator of interventricular dyssynchrony, was defined as the time interval between the onset of antegrade blood flow in the right ventricular outflow tract and the onset of antegrade blood flow in the LV outflow tract. Interventricular mechanical delay was estimated from pulsed-wave Doppler velocity signals recorded from the right ventricular and LV outflow tracts immediately proximal to the respective semilunar valves. 14 LV volumes, LVEF, LV mass, LV shape, diastolic function, and severity of MR were assessed at baseline and at 6 and 12 months to characterize the time-dependent changes in LV remodeling with CRT and to determine whether reverse remodeling persisted to 12 months. Echocardiographic and clinical indices, including NYHA symptom class, 6-minute hall walk distance, and QoL, were evaluated in all patients with data sets at 1 or more of the following time points: Baseline, 6 months, and 12 months. The blinded phase of the MIRACLE study ended when all patients completed their 6-month visit, at which time they were informed of their randomized assignment. Only patients randomized to CRT ON for the first 6 months were eligible for this analysis of continuous CRT from baseline through 12 months. The institutional review board at each investigator site approved the study protocol, and all patients gave written informed consent.
Statistical Methods
Descriptive statistics for baseline demographics are presented as both means and SDs for continuous variables or percentages for discrete variables. Differences between means for ischemic and nonischemic patient groups were assessed with unpaired t tests. For discrete variables, distributions between groups were compared with 2 tests. Random effects regression models were used to identify significant changes in echocardiographic and clinical parameters over time with measurements at baseline and 6 and 12 months for all CRT patients. Patients were included in each analysis if measurements were available at 1 or more time points. If the overall test of time effect was significant in a model, then pairwise differences were examined. Similar statistical methodology was used to assess changes in echocardiographic and clinical parameters between CRT ischemic and CRT nonischemic patients. Because there were differences between ischemic and nonischemic patients with respect to several baseline risk factors (age, gender, QRS duration, LVEF, LVESV, and LVEDV), the models for these analyses included covariates for each risk factor. The relationship between etiology and LVEDV over time was evaluated with a mixed linear regression model. Potential confounding factors were identified by comparing baseline variables between ischemic and nonischemic patients. Age, gender, heart rate, and QRS width were significantly different between ischemic and nonischemic patients, and these variables were adjusted for in the mixed linear model.
All statistical analyses were conducted with software from SAS, Inc. Statistical tests with probability values less than 0.05 were considered statistically significant.
Results
Baseline clinical demographics are shown for all 228 patients with continuous CRT therapy and with the popu-lation divided by cause of heart failure ( Table 1) . LV end-diastolic (EDD) and end-systolic (ESD) diameters decreased progressively over 12 months (Table 2) , which suggests ongoing reverse remodeling. LVEDV and LVESV were both significantly (PϽ0.007 and PϽ0.0001, respectively) reduced at 1 year compared with baseline; however, the mean volume reduction was greater at 6 months than at 12 months, which indicates that LV volumes trended toward baseline volumes by 12 months (Table 2) . Over the same time period, there was a progressive increase in mean LVEF from 24% at baseline to 29% at 6 months and 31% at 12 months.
We investigated whether baseline demographics (age Ͼ65 years, gender, NYHA symptom class, QRS duration Ͼ170 ms, and LVEF Ͻ25%) correlated with changes in LVEDV at 6 and 12 months. Of these parameters, age Յ65 years (Pϭ0.005), female gender (Pϭ0.045), QRS duration Ͼ170 ms (Pϭ0.007), and LVEF Ͻ25% (Pϭ0.040) all correlated with decreases in LVEDV and reverse remodeling between baseline and 6 months. However, by 12 months the only parameters that correlated with changes in LVEDV were QRS Ͼ170 ms (Pϭ0.018) and LVEF Ͻ25% (Pϭ0.023), not age (Pϭ0.094) or gender (Pϭ0.248).
The proportion of patients who had a decrease in LVEDV at 6 months was 71% (95% CI 64% to 77%), which declined to 58% at 12 months (95% CI 50% to 66%; PϽ0.05). Similarly, the proportion of patients with decreased LVESV was 74% at 6 months (95% CI 67% to 80%), which declined to 60% at 12 months (95% CI 52% to 68%; PϽ0.05). However, the proportion of patients with increased LVEF remained constant from 75% (95% CI 69% to 81%) at 6 months to 74% (95% CI 67% to 81%) at 12 months (PϭNS).
In addition, LV mass decreased significantly from baseline at 6 and 12 months (Pϭ0.012 and PϽ0.0001, respectively). The improvement in LVEF and concomitant reduction in LV mass at 12 months was associated with decreases in systolic and diastolic sphericity indices (Pϭ0.003 and Pϭ0.001, respectively), consistent with change in LV cavity shape toward a more ellipsoidal configuration. The change to a more mechanically advantageous LV systolic cavity shape at 6 and 12 months (Pϭ0.004 and Pϭ0.003, respectively) was likely due to acute changes in the pattern of contraction after the initiation of CRT. This reverse LV remodeling with CRT was accompanied by a decrease in the severity of MR at 6 and at 12 months, although whether the change in LV shape preceded the reduction in MR or vice versa was not discernible from the present study.
Diastolic measures of LV function demonstrated systematic improvement after 6 months of CRT, with further sustained improvements at 12 months. LV filling time increased progressively from baseline to 12 months. The transmitral E/A velocity ratio and myocardial performance index both decreased from baseline through 12 months, which indicates improvement in diastolic LV function. Furthermore, there was shortening of interventricular mechanical delay and isovolumic contraction time at 6 and 12 months, consistent with increased interventricular and intraventricular synchrony ( Table 2) .
The reduced LV reverse remodeling that occurred between 6 and 12 months was unlikely due to changes in heart failure therapy. The dose of ␤-blockers was kept constant for the first 6 months of the study, and even though changes were permitted between 6 and 12 months, only 10 patients had a dosage increase, 7 patients were started on ␤ blockers, and the dose was decreased in 1 patient. Our expectation was that ␤-blockers would be associated with further volume reduction and continued reverse remodeling rather than the late recurrent LV dilation observed between 6 and 12 months.
We sought to explain our finding that both LVEDV and LVESV increased from 6 to 12 months, which indicated late recurrent LV dilatation. Consistent with previous reports, 8, 15 CRT does not appear to have the same effect on reverse remodeling in patients with ischemic heart failure as in those with nonischemic heart failure. For this reason, we evaluated the time-dependent changes in LV volumes by cause of heart failure at 6 and 12 months using a random effects model ( Table 3 ). The models were adjusted for age, gender, and baseline values of heart rate, QRS duration, ejection fraction, and end-diastolic and end-systolic volumes because of differences between ischemic and nonischemic patients with respect to these variables (Table  1) . When these variables were adjusted for, the changes in LVEDV remained significantly different between patients with ischemic versus nonischemic heart failure. In the ischemic heart failure patients, the favorable reduction in LV volumes at 6 months had regressed by 12 months (Table 3) . By contrast, in the nonischemic patients, the reduction in LV volumes at 6 months was more than 3-fold greater than in the ischemic patients, and this difference was sustained at 12 months (Table 3 ). The different schedules of remodeling by heart failure origin may explain the changes in LV volumes between 6 and 12 months when the patient cohort is considered as a whole. The salutary effects of CRT on NYHA symptom class, 6-minute hall walk distance, and QoL score achieved at 6 months were sustained at 12 months (Table 2) . Furthermore, there were no differences with regard to clinical end points in the ischemic versus nonischemic patients at 6 or 12 months (Table 3 ). Prior analysis of the same 3 primary end points in the MIRACLE Study Program, which includes patients from the MIRACLE, MIRACLE ICD, and InSync III clinical trials who received continuous CRT, showed that the significant improvements in NYHA symptom class, 6-minute hall walk distance, and QoL measured by the MLWHF questionnaire 12 were sustained up to 18 months. 16 There was no difference in clinical end points between the ischemic and nonischemic groups at any time point out to 18 months. 16 
Discussion
Moderate to severe (NYHA III/IV) heart failure is characterized by progressive ventricular remodeling consisting of LV dilatation, cavity distortion, and deterioration in pump function that portends a poor prognosis. 17 Most large multicenter heart failure trials have shown that pharmaceutical agents, including angiotensin-converting enzyme (ACE) inhibitors, ARBs, and ␤-adrenergic receptor blockers, attenuate rather than reverse LV remodeling, with a few notable exceptions. 18, 19 In the majority of patients, CRT is associated with symptomatic improvement, increased exercise capacity, improved QoL, and reduced death and hospitalization. 1,9,10 CRT confers incremental benefit over optimal medical therapy by resynchronizing right and left ventricular contraction that mediates reversal of the remodeling process. Improvements in cardiac structure, geometry, and function with CRT likely contribute to the consistent symptomatic benefits.
The major findings of the present study were that CRT resulted in progressive reverse remodeling that persisted to 12 months in patients with moderate to severe heart failure. Although LV volumes were reduced compared with baseline after 12 months of CRT, the percentage of patients demonstrating progressive reduction in LV size decreased from 6 to 12 months, which reflects a variability of response when LV volumes are used as an end point. Most previous studies have been unblinded; only a few have described changes in echocardiographic measurements of LV size, and those that did usually involved small patient cohorts and short follow-up periods of between 1 and 6 months. 6,15,20 -22 The only randomized, double-blind CRT trial with 12-month follow-up used linear echocardiographic measurements of LV size and also showed reverse LV remodeling in heart failure patients in sinus rhythm. 5 We showed that after 12 months of CRT, not only did LV volumes decrease, but LV function (LVEF) improved progressively, LV mass regressed, LV cavity shape was restored toward normal, and the severity of MR decreased, and we showed that the magnitude of these changes was greater in nonischemic than ischemic heart failure patients.
Supportive evidence for the sustained reverse remodeling at 12 months was provided by concomitant improvements in LV diastolic function parameters. There was progressive lengthening of LV diastolic filling time and shortening of interventricular mechanical delay, which indicates a sustained decrease in LV dyssynchrony. The changes in transmitral velocity (E/A) ratio at 6 months were sustained at 12 months, and myocardial performance index improved from 6 to 12 months owing to progressive shortening of isovolumic contraction time and IVRT. Importantly, this ongoing structural and functional reverse remodeling with CRT impacted favorably and significantly on NYHA symptom class, 6-minute hall walk distance, and QoL at 6 months, and these beneficial effects continued through 12 months.
In spite of the major changes in LV architecture, myocardial mass, and systolic and diastolic function and the accompanying clinical improvement to 12 months, there was evidence of late, recurrent LV cavity dilatation between 6 and 12 months. The significant reduction in LVEDV and LVESV present at 6 months was attenuated at 12 months. This late LV dilatation was unlikely due to changes in heart failure medications between 6 and 12 months, because review of the case record forms showed that only 10 patients increased their dose of ␤-blockers, and only 7 patients were started on ␤-blockers. ␤-Blockers would be expected to facilitate further LV volume reduction and continued reverse remodeling rather than the LV dilatation that we observed. We demonstrated that age Յ65 years, female gender, QRS duration Ͼ170 ms, and LVEF Ͻ25% all correlated with decreases in LVEDV and reverse remodeling from baseline to 6 months. In contrast, by 12 months, the only parameters that correlated with changes in LVEDV were QRS duration Ͼ170 ms and LVEF Ͻ25%.
Because LV cavity dilatation is associated with deterioration in contractile function and adverse clinical outcome, and because of previously reported differential remodeling by cause of heart failure, 8 we divided our patient cohort into those with nonischemic and those with ischemic heart failure. At 6 months, changes in LV volumes in the nonischemic patients were more than 2-fold greater in ischemic patients, although both groups were significantly improved from baseline. However, by 12 months, LV volumes in the ischemic patients had returned almost to baseline values, whereas in nonischemic patients, both LVEDV and LVESV remained significantly reduced at 12 months compared with baseline values (Table 3) . Comparison of baseline variables between the ischemic and nonischemic patients revealed a number of potential confounding factors. Age, gender, heart rate, QRS duration, and end-diastolic and end-systolic volumes were all significantly different between ischemic and nonischemic patients. However, when these variables were adjusted for, the changes in LV volumes remained significantly different between ischemic and nonischemic patients. The late, recurrent LV dilatation that occurred between 6 and 12 months in the ischemic patients may be related to the natural progression of LV dysfunction due to 
CLINICAL PERSPECTIVE
Cardiac resynchronization therapy (CRT) is a novel and effective treatment for patients with New York Heart Association (NYHA) class III/IV heart failure refractory to optimal medical therapy and with prolonged QRS duration. CRT improves exercise capacity, NYHA symptom class, and quality of life and reverses ventricular remodeling. How long the reverse remodeling and symptomatic benefit are sustained is unknown. Quantitative analysis of serial echocardiograms from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) trial demonstrated continuing reverse structural and functional remodeling at 1 year. Left ventricular (LV) volumes, mass, and severity of mitral regurgitation decreased, whereas ejection fraction and diastolic function improved. The only parameters that correlated with reverse remodeling at 1 year were baseline ejection fraction Ͻ25% and QRS duration Ͼ170 ms. The favorable reduction in LV volumes in the ischemic heart failure patients at 6 months had regressed by 1 year, whereas in the nonischemic patients, the reduction in LV volumes at 6 months was more than 3-fold greater than that in ischemic patients, and this difference was sustained at 1 year. When adjustments were made for differences in age, gender, and baseline heart rate, QRS duration, LV volumes, and ejection fraction, the changes in LV volumes remained significantly different between patients with ischemic versus nonischemic heart failure. These important clinical data show that reverse LV remodeling and symptom benefit with CRT are sustained at 1 year in advanced (NYHA class III/IV) heart failure, although reverse remodeling is less extensive in ischemic than in nonischemic patients.
